Skip to content
OpenCapital
Get started

Tango Therapeutics TNGX Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Guardant Health logo
Guardant HealthGH
——
BillionToOne, Inc. logo
BillionToOne, Inc. BLLN
——

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
Tango Therapeutics (TNGX) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $313.61M in Q1 2026.
What is the long-term trend for Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
Over 5 years (2020 to 2025), Tango Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value has grown at a -60.9% compound annual growth rate (CAGR), from $6.63B to $60.72M.